alexa Abstract | Synthesis and in vitro anticancer evaluation of 2-methylphenyl sydnone derivatives against Human breast cancer cell line MDA-MB-231 and Human prostate cancer cell line PC3

Journal of Chemical and Pharmaceutical Research
Open Access

OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Original Articles Open Access


Heterocyclic analogues of 1, 2, 3-oxadiazolium-5-olate along with pyrazole ring and isoxazole ring have been designed for antineoplastic evaluation. A series of novel 4-[5-(aryl)-4, 5-dihydro-(1H-pyrazole/1-phenylpyrazol/ isoxazole)-3-yl]-3-(2-methyphenyl)-1,2,3-oxadiazolium-5-olates has been synthesized and evaluated against human prostate cancer cell line PC3 and human breast cancer cell line MDA-MB-231. Compound 2C was found to have moderate cytotoxic activity (GI50=56.9μg/ml). Further designing with modifications and in vivo study of synthesized 1, 2, 3-oxadiazolium-5-olates may give a ray of light to search for a potent antitumor molecule.

To read the full article Peer-reviewed Article PDF image

Author(s): Sachin K Bhosalea Shreenivas R Deshpandeb and Rajendra D Waghc


1, 2, 3-oxadiazolium-5-olate, sydnone, anticancer, pyrazole, isoxazole, anticancer,breast cancer,prostate cancer

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version